According to the Chinese Society of Clinical Oncology guidelines, pembrolizumab is recommended for the first-line treatment of advanced driver negative NSCLC (Grade I recommendation), with PD-L1 TPS ≥ 50% as class 1A evidence and PD-L1 TPS ≥ 1% as class 2A evidence. Here, CD274 is linked to non-small cell lung carcinoma.